Intensity-Modulated Proton Therapy Reduces Acute Toxicity While Maintaining Oncologic Equivalence in Nasopharyngeal Carcinoma: A Five-Year Case-Control Analysis
Posted innews Oncology Otorhinolaryngology

Intensity-Modulated Proton Therapy Reduces Acute Toxicity While Maintaining Oncologic Equivalence in Nasopharyngeal Carcinoma: A Five-Year Case-Control Analysis

A case-control study comparing IMPT and IMRT for nasopharyngeal carcinoma shows that IMPT significantly reduces grade 2+ acute toxicities without compromising long-term survival or local-regional control, suggesting a superior therapeutic index during the acute treatment phase.
Closing the Gap: Why Patient Perspectives Predict Survival Better Than Clinician Ratings in Sclerotic cGVHD
Posted inDermatology news Oncology Transplantation

Closing the Gap: Why Patient Perspectives Predict Survival Better Than Clinician Ratings in Sclerotic cGVHD

A multicenter study reveals significant discordance between clinician and patient assessments of skin cGVHD. While both correlate with survival, patient-reported outcomes are uniquely predictive of mortality in sclerotic disease, highlighting the need for integrated assessment models in clinical practice.
Long-Term Survival vs. Short-Term Quality of Life: Deciding the Fate of Esophageal Cancer Responders
Posted inGeneral Surgery news Oncology

Long-Term Survival vs. Short-Term Quality of Life: Deciding the Fate of Esophageal Cancer Responders

A decision analytical model based on the SANO trial suggests that while active surveillance offers short-term quality-of-life benefits, standard esophagectomy remains superior for maximizing long-term survival and quality-adjusted life-years in patients achieving a clinical complete response after neoadjuvant chemoradiation.
Sacituzumab Govitecan plus Pembrolizumab Extends Progression-Free Survival in First-Line PD-L1-Positive Advanced TNBC
Posted innews Oncology

Sacituzumab Govitecan plus Pembrolizumab Extends Progression-Free Survival in First-Line PD-L1-Positive Advanced TNBC

The phase 3 ASCENT-04/KEYNOTE-D19 trial demonstrates that sacituzumab govitecan plus pembrolizumab significantly improves progression-free survival and duration of response compared to standard chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1-positive advanced triple-negative breast cancer.